These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

588 related articles for article (PubMed ID: 19897178)

  • 21. Dose equivalents for second-generation antipsychotics: the minimum effective dose method.
    Leucht S; Samara M; Heres S; Patel MX; Woods SW; Davis JM
    Schizophr Bull; 2014 Mar; 40(2):314-26. PubMed ID: 24493852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disposition of haloperidol pyridinium and reduced haloperidol pyridinium in schizophrenic patients: no relationship with clinical variables during short-term treatment.
    Ulrich S; Neuhof S; Braun V; Danos P; Pester U; Hoy L
    J Clin Psychopharmacol; 2000 Apr; 20(2):210-9. PubMed ID: 10770460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics.
    Singh MM; Kay SR
    Psychopharmacologia; 1975 Aug; 43(2):103-13. PubMed ID: 1103205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients.
    Breitbart W; Marotta R; Platt MM; Weisman H; Derevenco M; Grau C; Corbera K; Raymond S; Lund S; Jacobson P
    Am J Psychiatry; 1996 Feb; 153(2):231-7. PubMed ID: 8561204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An importance of dose in antipsychotic combination therapy for schizophrenia.
    Suzuki T
    J Clin Psychopharmacol; 2011 Jun; 31(3):399; author reply 399-400. PubMed ID: 21532376
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of the effects of clozapine, haloperidol, chlorpromazine and d-amphetamine on performance on a time-constrained progressive ratio schedule and on locomotor behaviour in the rat.
    Mobini S; Chiang TJ; Ho MY; Bradshaw CM; Szabadi E
    Psychopharmacology (Berl); 2000 Sep; 152(1):47-54. PubMed ID: 11041315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of neuroleptics and of potential new antipsychotic agents (MJ 13859-1 and MJ 13980-1) on a monkey model of tardive dyskinesia.
    Kovacic B; Ruffing D; Stanley M
    J Neural Transm; 1986; 65(1):39-49. PubMed ID: 2870130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk of ischemic stroke associated with the use of antipsychotic drugs in elderly patients: a retrospective cohort study in Korea.
    Shin JY; Choi NK; Lee J; Seong JM; Park MJ; Lee SH; Park BJ
    PLoS One; 2015; 10(3):e0119931. PubMed ID: 25790285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Erythrocyte ketone reductase activity, total plasma haloperidol and acute psychoses].
    Dutoit D; Thomas P; Leroux JM; Vaiga G; Pommery J; Cottencin O; Erb F; Goudemand M
    Encephale; 1995; 21(6):417-24. PubMed ID: 8674466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative doses and costs of antipsychotic medication.
    Davis JM
    Arch Gen Psychiatry; 1976 Jul; 33(7):858-61. PubMed ID: 8024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics.
    Rey MJ; Schulz P; Costa C; Dick P; Tissot R
    Int Clin Psychopharmacol; 1989 Apr; 4(2):95-104. PubMed ID: 2568378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A longitudinal therapeutic comparison between two prototypic neuroleptics (haloperidol and chlorpromazine) in matched groups of schizophrenics. Nontherapeutic interactions with trihexyphenidyl. Theoretical implications for potency differences.
    Singh MM; Kay SR
    Psychopharmacologia; 1975 Aug; 43(2):115-21. PubMed ID: 1103206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
    Conley RR; Tamminga CA; Bartko JJ; Richardson C; Peszke M; Lingle J; Hegerty J; Love R; Gounaris C; Zaremba S
    Am J Psychiatry; 1998 Jul; 155(7):914-20. PubMed ID: 9659857
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1130-8. PubMed ID: 17513028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antipsychotic drug use in the United States, 1976-1985.
    Wysowski DK; Baum C
    Arch Gen Psychiatry; 1989 Oct; 46(10):929-32. PubMed ID: 2572207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Haloperidol versus chlorpromazine for treatment of schizophrenia.
    Leucht C; Kitzmantel M; Chua L; Kane J; Leucht S
    Schizophr Bull; 2008 Sep; 34(5):813-5. PubMed ID: 18658127
    [No Abstract]   [Full Text] [Related]  

  • 38. Correction of serum neuroleptic activity for blood-to-brain distribution: a method that may render radioreceptor assay results comparable between neuroleptics.
    Young AS; Faraone SV; Brown WA
    J Clin Psychopharmacol; 1989 Oct; 9(5):361-3. PubMed ID: 2571620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dose Equivalents for Antipsychotic Drugs: The DDD Method.
    Leucht S; Samara M; Heres S; Davis JM
    Schizophr Bull; 2016 Jul; 42 Suppl 1(Suppl 1):S90-4. PubMed ID: 27460622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population pharmacokinetics of haloperidol using routine clinical pharmacokinetic data in Japanese patients.
    Yukawa E; Hokazono T; Yukawa M; Ichimaru R; Maki T; Matsunaga K; Ohdo S; Anai M; Higuchi S; Goto Y
    Clin Pharmacokinet; 2002; 41(2):153-9. PubMed ID: 11888334
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.